Baricitinib
- Generic Name
- Baricitinib
- Brand Names
- Olumiant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H17N7O2S
- CAS Number
- 1187594-09-7
- Unique Ingredient Identifier
- ISP4442I3Y
- Background
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...
- Indication
In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...
- Associated Conditions
- Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
- Conditions
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- M Abdur Rahim Medical College and Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04693026
- Locations
- 🇧🇩
M. Abdur Rahim Medical College Hospital, Dinajpur, Bangladesh
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-06-28
- Target Recruit Count
- 1010
- Registration Number
- NCT04640168
- Locations
- 🇺🇸
Cedars Sinai Medical Center, West Hollywood, California, United States
🇺🇸University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States
🇺🇸University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 8
- Registration Number
- NCT04517253
- Locations
- 🇯🇵
Tokyo Medical And Dental University Medical Hospital, Bunkyō, Tokyo, Japan
🇯🇵Hiroshima University Hospital, Hiroshima, Japan
🇯🇵Wakayama Medical University Hospital, Wakayama, Japan
A Study of Baricitinib (LY3009104) in Participants With COVID-19
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1525
- Registration Number
- NCT04421027
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Westchester General Hospital, Miami, Florida, United States
🇺🇸Community Hospital South, Indianapolis, Indiana, United States
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2022-03-14
- Target Recruit Count
- 1033
- Registration Number
- NCT04401579
- Locations
- 🇺🇸
Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States
🇺🇸University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States
🇺🇸University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States
Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 13
- Registration Number
- NCT04399798
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-18
- Target Recruit Count
- 1167
- Registration Number
- NCT04390464
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
Randomised Evaluation of COVID-19 Therapy
- Conditions
- Interventions
- Drug: Lopinavir-RitonavirBiological: Convalescent plasmaBiological: ImmunoglobulinDrug: CorticosteroidDrug: Synthetic neutralising antibodiesDrug: EmpagliflozinDrug: AnakinraDrug: High Dose CorticosteroidDrug: SotrovimabDrug: PaxlovidDrug: Baloxavir MarboxilDrug: HydroxychloroquineDrug: AzithromycinDrug: TocilizumabDrug: AspirinDrug: Dimethyl fumarateDrug: ColchicineDrug: BaricitinibDrug: OseltamivirDrug: Molnupiravir
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70000
- Registration Number
- NCT04381936
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 6
- Registration Number
- NCT04373044
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Safety and Efficacy of Baricitinib for COVID-19
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT04340232
- Locations
- 🇺🇸
University of Colorado, Denver, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.